Luciano Dolgetta
Managing Partner at Alchemy Capital Partners
New York, New York
Luciano Dolgetta, Managing Partner at Alchemy Capital Partners is an active investor based in New York, New York. This profile covers what Luciano Dolgetta backs, at which stage, and how founders can reach out in 2026.
- Investor type
- VC
- Stages
- SeedSeries A
- Location
- New York, New York
- Typical check
- $625K
How to reach Luciano Dolgetta
Angels and operators like Luciano Dolgetta reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Connect with Luciano Dolgetta
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise.
Frequently Asked Questions
Who is Luciano Dolgetta?
Luciano Dolgetta is an active investor, Managing Partner at Alchemy Capital Partners. Round Funded tracks their focus and activity alongside thousands of investors.
What stage does Luciano Dolgetta invest at?
Luciano Dolgetta typically invests at Seed and Series A. Lead with traction that fits the stage when you reach out.
What is Luciano Dolgetta's typical check size?
Luciano Dolgetta typically writes checks around $625K. Use it as a signal for whether your raise fits their stage.
How do I contact Luciano Dolgetta?
Unlock Luciano Dolgetta's verified email on Round Funded and send a personalized pitch. We surface only deliverable contacts so your outreach lands.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.